Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone to Start Combo Trial of its PD-L1 with Bayer's Stivarga for Gastric Cancer

publication date: Jun 11, 2019

CStone Pharma of Suzhou will test its PD-L1 monoclonal antibody in combination with Bayer Healthcare's Stivarga® (regorafenib) as a treatment for multiple cancers including gastric cancer. Stivarga is a multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R, etc. The two companies described the collaboration as a global effort with a China emphasis. CStone will be the study sponsor and Bayer will provide regorafenib throughout the clinical trial program. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.